Drug Trial Radar · NCT02865538
Evaluation of the Pharmacokinetics and Safety of BAY3427080 (NT-814) in Post-Menopausal Women With Vasomotor Symptoms
Last checked: Nov 20, 2026Latest source record: Feb 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
76
Actual
Start
Aug 1, 2016
Primary completion
Mar 28, 2017
Study completion Mar 28, 2017
Sponsor
- Lead sponsor
- BayerBayer (BAYRY)
- Sponsor type
- Industry
- Collaborators
- Nerre Therapeutics Ltd.
- First posted
- Aug 12, 2016
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 45 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center, double-blind, randomized, placebo-controlled multiple ascending dose study in post-menopausal women with vasomotor symptoms. Single ascending doses of NT-814 will be investigated in 4 cohorts. Each cohort will comprise of 20 subjects. Subjects will be dosed for 14 days.
Conditions
- Post-menopausal Vasomotor Symptoms
Interventions
BAY3427080Drug
Placebo (for BAY3427080)Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Observed Plasma Concentration (Cmax) of BAY3427080Time frame: On Day 1, Day 7 (Pre-dose; 0.5; 1.0; 1.5; 2.0; 2.5; 3.0; 4.0; 5.0; 6.0; 8.0; 12.0; 24.0 hours) and on Day 14 (Pre-dose; 0.5; 1.0; 1.5; 2.0; 2.5; 3.0; 4.0; 5.0; 6.0; 8.0; 12.0; 24.0, 48.0, 72.0 hours)
- Time to Reach Maximum Observed Drug Concentration in Plasma (Tmax) of BAY3427080Time frame: On Day 1, Day 7 (Pre-dose; 0.5; 1.0; 1.5; 2.0; 2.5; 3.0; 4.0; 5.0; 6.0; 8.0; 12.0; 24.0 hours) and on Day 14 (Pre-dose; 0.5; 1.0; 1.5; 2.0; 2.5; 3.0; 4.0; 5.0; 6.0; 8.0; 12.0; 24.0, 48.0, 72.0 hours)
- Area Under the Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC0-∞) of BAY3427080Time frame: Day 1 (pre-dose and post-dose (0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 4.0, 5.0, 6.0, 8.0, 12.0 and 24.0 hours)
- Area Under the Concentration-time Curve (AUC) From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-τ) of BAY3427080Time frame: On Day 1, Day 7 (Pre-dose; 0.5; 1.0; 1.5; 2.0; 2.5; 3.0; 4.0; 5.0; 6.0; 8.0; 12.0; 24.0 hours) and on Day 14 (Pre-dose; 0.5; 1.0; 1.5; 2.0; 2.5; 3.0; 4.0; 5.0; 6.0; 8.0; 12.0; 24.0, 48.0, 72.0 hours)
- Terminal Elimination Half-life (t½) of BAY3427080Time frame: On Day 1, Day 7 (Pre-dose; 0.5; 1.0; 1.5; 2.0; 2.5; 3.0; 4.0; 5.0; 6.0; 8.0; 12.0; 24.0 hours) and on Day 14 (Pre-dose; 0.5; 1.0; 1.5; 2.0; 2.5; 3.0; 4.0; 5.0; 6.0; 8.0; 12.0; 24.0, 48.0, 72.0 hours)
- Apparent Clearance (CL/F) of BAY3427080Time frame: On Day 1, Day 7 (Pre-dose; 0.5; 1.0; 1.5; 2.0; 2.5; 3.0; 4.0; 5.0; 6.0; 8.0; 12.0; 24.0 hours) and on Day 14 (Pre-dose; 0.5; 1.0; 1.5; 2.0; 2.5; 3.0; 4.0; 5.0; 6.0; 8.0; 12.0; 24.0, 48.0, 72.0 hours)
- Number of Participants With Clinically Significant Abnormalities Detected Upon Physical Examination.Time frame: At day 14
- Number of Participants With Clinically Significant Abnormalities on the 12-lead ECGsTime frame: At day 14
- Number of Participants With Arrhythmias as Assessed by Continuous Holter Monitoring.Time frame: Baseline (day -1) and day 14
- Change From Baseline at Day 14 in Vital Signs: Diastolic Blood Pressure (Standing)Time frame: Baseline and day 14
- Change From Baseline at Day 14 in Vital Signs: Diastolic Blood Pressure (Sitting)Time frame: Baseline and day 14
- Change From Baseline at Day 14 in Vital Signs: Systolic Blood Pressure (Standing)Time frame: Baseline and day 14
- Change From Baseline at Day 14 in Vital Signs: Systolic Blood Pressure (Sitting)Time frame: Baseline and day 14
- Change From Baseline at Day 14 in Vital Signs: Pulse RateTime frame: Baseline and day 14
- Change From Baseline at Day 14 in Vital Signs: Respiratory RateTime frame: Baseline and day 14
- Change From Baseline at Day 14 in Vital Signs: Oxygen SaturationTime frame: Baseline and day 14
- Change From Baseline at Day 14 in Vital Signs: Oral Body TemperatureTime frame: Baseline and day 14
- Change From Baseline at Day 14 in Vital Signs: WeightTime frame: Baseline and day 14
- Change From Baseline at Day 15 for Laboratory Hormones Results : Adrenocorticotropic Hormone (ADTH) and Estradiol.Time frame: Baseline and day 15
- Change From Baseline at Day 15 for Laboratory Hormones Results: Follicle Stimulating HormoneTime frame: Baseline and day 15
- Change From Baseline at Day 15 for Laboratory Hormones Results : Triiodothyronine UptakeTime frame: Baseline and day 15
- Change From Baseline at Day 15 for Laboratory Hormones Results: ThyrotropinTime frame: Baseline and day 15
- Change From Baseline at Day 15 for Laboratory Hormones Results : Cortisol, Testosterone, Thyroxine and TriiodothyronineTime frame: Baseline and day 15
- Change From Baseline at Day 14 for Clinical Laboratory Parameters LIPIDS : Cholesterol, Triglycerides, HDL Cholesterol and LDL Cholesterol.Time frame: Baseline and day 14
- Change From Baseline at Day 14 for Laboratory Parameters HEMATOLOGY: Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils and Immature Granulocytes.Time frame: Baseline and day 14
- Change From Baseline at Day 14 for Clinical Laboratory Parameters HEMATOLOGY: Leukocytes, Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils, Immature Granulocytes and Platelets.Time frame: Baseline and day 14
- Change From Baseline at Day 14 for Laboratory Parameters HEMATOLOGY: Hemoglobin and Erythrocytes Mean Corpuscular Hemoglobin ConcentrationTime frame: Baseline and day 14
- Change From Baseline at Day 14 for Laboratory Parameters HEMATOLOGY: ErythrocytesTime frame: Baseline and day 14
- Change From Baseline at Day 14 for Laboratory Parameters HEMATOLOGY: Erythrocytes Mean Corpuscular Volume and Mean Platelet Volume.Time frame: Baseline and day 14
- Change From Baseline at Day 14 for Laboratory Parameters HEMATOLOGY: Erythrocytes Mean Corpuscular HemoglobinTime frame: Baseline and day 14
- Change From Baseline at Day 14 for Laboratory Parameters HEMATOLOGY: Erythrocytes Distribution Width.Time frame: Baseline and day 14
- Change From Baseline at Day 14 for Laboratory Parameters HEMATOLOGY: Hematocrit.Time frame: Baseline and day 14
- Change From Baseline at Day 14 for Laboratory Parameters CHEMISTRY: Protein and Albumin.Time frame: Baseline and day 14
- Change From Baseline at Day 14 for Laboratory Parameters CHEMISTRY: Alkaline Phosphatase, Alanine Aminotransferase, Aspartate Aminotransferase, Gamma Glutamyl Transferase and Creatine KinaseTime frame: Baseline and day 14
- Change From Baseline at Day 14 for Laboratory Parameters CHEMISTRY: Urate, Bilirubin and Creatinine.Time frame: Baseline and day 14
- Change From Baseline at Day 14 for Clinical Laboratory Parameters CHEMISTRY: Sodium, Potassium, Chloride, Bicarbonate, Calcium, Phosphate, Glucose, Magnesium and Urea Nitrogen.Time frame: Baseline and day 14
- Laboratory Parameters CHEMISTRY: Glomerular Filtration Rate African at BaselineTime frame: At Baseline
- Laboratory Parameters CHEMISTRY: Glomerular Filtration Rate Caucasian at BaselineTime frame: At Baseline
- Change From Baseline at Day 14 for COAGULATION: Prothrombin International Normalized Ratio (INR)Time frame: Baseline and day 14
- Change From Baseline at Day 14 for COAGULATION: Prothrombin Time and Activated Partial Thromboplastin TimeTime frame: Baseline and day 14
- Heart Rate (HR) - Change From Baseline (Day -1) at Day 14Time frame: Baseline (day -1) and day 14
- Mean PR Interval - Change From Baseline (Day -1) at Day 14Time frame: Baseline (day -1) and day 14
- Mean QRS Duration - Change From Baseline (Day -1) at Day 14Time frame: Baseline (day -1) and day 14
- Mean QT Interval - Change From Baseline (Day -1) at Day 14Time frame: Baseline (day -1) and day 14
- Mean QTcF Interval (Fridericia's Correction Formula, QTcF) - Change From Baseline (Day -1) at Day 14Time frame: Baseline (day -1) and day 14
- Mean QTcB Interval (Bazett's Correction Formula, QTcB) - Change From Baseline (Day -1) at Day 14Time frame: Baseline (day -1) and day 14
- Nature and Severity of Adverse Events (AEs) up to Day 21Time frame: On or after first drug administration up to end of study (Day 21).
- Withdrawals Due to AEs up to Day 21Time frame: On or after first drug administration up to end of study (Day 21)
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Avail Clinical Research
DeLand, Florida
QPS/MRA (Miami Clinical Research)
Miami, Florida
ICON Clinical Research Unit
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.